The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation - Study design

Nephrology Dialysis Transplantation

Volumn 23, Issue 1, 2008, Pages 354-358

  Knoll, Greg A ^a,l   Cantarovitch, Marcelo ^b   Cole, Ed ^c   Gill, John ^d   Gourishankar, Sita ^e   Holland, Dave ^f   Kiberd, Bryce ^g   Muirhead, Norman ^h   Prasad, Ramesh ⁱ   Tibbles, Lee Anne ^j   Treleaven, Darin ^k   Fergusson, Dean ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j UNIVERSITY OF CALGARY   (Canada)

^k MCMASTER UNIVERSITY   (Canada)

^l UNIVERSITY OF OTTAWA   (Canada)

more..

Author keywords

ACE inhibitor; Kidney transplantation; Ramipril; Randomized trial

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ANEMIA; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; CHRONIC KIDNEY FAILURE; METHODOLOGY; MORTALITY; PROSPECTIVE STUDY; SURVIVAL RATE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DOUBLE-BLIND METHOD; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PROSPECTIVE STUDIES; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 44449094269     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm574     Document Type: Article

References (38)

1. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730
2. Laupacis A, Keown P, Pus N et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996; 50: 235-242
3. Russell JD, Beecroft M, Ludwin D, Churchill DN. The quality of life in renal transplantation-a prospective study. Transplantation 1992; 54: 656-660
4. 2001 Report, Volume 1: Dialysis and Renal Transplantation, Canadian Organ Replacement Register, Canadian Institute for Health Information: Ottawa, ON, 1 August 2001
5. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-313
6. United States Renal Data Systems - Data request April 2004. Requested through the website at: www usrds org 2004
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462
8. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
9. Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
10. Trivedi H, Lal SM. A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis. Renal Failure 2003; 25: 77-86
11. K/DOQI Clinical Practice Guidelines on Hypertension, and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 2004; 43: S1-S290
12. Shah N, Al Khoury S, Afzali B et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation 2006; 81: 1112-1118
13. Bestard O, Cruzado JM, Ercilla G et al. Rituximab induces regression of hepatitis C virus-related membranoproliferative glomerulonephritis in a renal allograft. Nephrol Dial Transplant 2006; 21: 2320-2324
14. Marks SD, McGraw M. Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatric Nephrol 2007; 22: 158-160
15. National Kidney FoundationK/DOQI Clinical Practice Guidelines for Chronic Kidney Disease:Evaluation, Classification and Stratification. Am J Kidney Dis 2003; 39[suppl 1]: S1-S266
16. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291-1295
17. Hohage H, Kleyer U, Bruckner D, August C, Zidek W, Spieker C. Influence of proteinuria on long-term transplant survival in kidney transplant recipients. Nephron 1997; 75: 160-165
18. Fernandez-Fresnedo G, Escallada R, Rodrigo E et al. The risk of cardiovascular disease associated with proteinuria in renal transplant patients. Transplantation 2002; 73: 1345-1348
19. Roodnat JI, Mulder PG, Rischen-Vos J et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001; 72: 438-444
20. Karthikeyan V, Karpinski J, Nair RC, Knoll G. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant 2004; 4: 262-269
21. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-2728
22. Evaluation Study Investigators. Effects of ramipril on cardiovascular, and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention. Lancet 2000; 355: 253-259
23. Lonn E, Yusuf S, Dzavik V et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-925
24. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Kidney Transplant Patients. Am J Transplant 2004; 4[suppl 7]: 13-53
25. Khan NA, McAlister FA, Campbell NR et al. The 2004 Canadian recommendations for the management of hypertension: Part II-Therapy. Canadian. J Cardiol 2004; 20: 41-54
26. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
27. Lauer MS, Topol EJ. Clinical trials-multiple treatments, multiple end points, and multiple lessons. JAMA 2003; 289: 2575-2577
28. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863
29. Wright JT, Jr, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431
30. Brooks R. EuroQol: the current state of play. Health Policy 1996; 37: 53-72
31. Fellstrom B, Holdaas H, Jardine A et al. Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation-experience from the ALERT trial. J Am Soc Nephrol 2003; 14: 187A(Abstract)
32. Holdaas H, Fellstrom B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024-2031
33. Lin J, Valeri AM, Markowitz GS, D'Agati VD, Cohen DJ, Radhakrishnan J. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002; 73: 783-788
34. Radermacher J, Mengel M, Ellis S et al. The renal arterial resistance index and renal allograft survival. N Engl J Med 2003; 349: 115-124
35. Jardine AG, Holdaas H, Fellstrom B et al. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study. Am J Transplant 2004; 4: 988-995
36. Fellstrom B, Holdaas H, Jardine AG et al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004; 66: 1549-1555
37. Fellstrom B, Holdaas H, Jardine AG et al. Risk factors for reaching renal endpoints in the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005; 79: 205-212
38. Radermacher J, Mengel M, Ellis S et al. The renal arterial resistance index and renal allograft survival. N Engl J Med 2003; 349: 115-124